Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

Esmail Mutahar Al-Ezzi,Husam Alqaisi,Sarah L. Picardo,Marco Adelmo James Iafolla,Srikala S. Sridhar,Adrian G. Sacher,Nazanin Fallah-Rad,Charles Catton,Padraig Warde,Robert J. Hamilton,Neil Fleshner,Alexandre R. Zlotta,Aaron Richard Hansen

Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

2020

Esmail Mutahar Al-Ezzi
Husam Alqaisi
Sarah L. Picardo
Marco Adelmo James Iafolla
Srikala S. Sridhar
Adrian G. Sacher
Nazanin Fallah-Rad
Charles Catton
Padraig Warde
Robert J. Hamilton
Neil Fleshner
Alexandre R. Zlotta
Aaron Richard Hansen

225Background: Radium-223 (Ra-223) improved overall survival (OS) in men with mCRPC with predominantly bone metastases. We analyzed their survival outcomes to identify factors associated with progn...

Keywords:

Prostate cancer
Oncology
Castration
Pathology
Internal medicine
Medicine
Radium-223
castration resistant
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations